Covered recipient · General Payments record
JOYCE ANN O'SHAUGHNESSY
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$132,489.71
131 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $96,689.55 | 57 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,925.00 | 4 |
| Travel and Lodging | $12,815.44 | 18 |
| Food and Beverage | $2,059.76 | 40 |
| Long term medical supply or device loan | $999.96 | 12 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $28,990.66 | 14 |
| Eli Lilly and Company | $22,327.87 | 25 |
| PFIZER INC. | $9,501.88 | 6 |
| AstraZeneca Pharmaceuticals LP | $8,541.34 | 7 |
| Stemline Therapeutics Inc. | $7,432.58 | 9 |
| Daiichi Sankyo Inc. | $7,249.91 | 5 |
| Lilly USA, LLC | $6,562.50 | 2 |
| Genentech USA, Inc. | $6,116.30 | 8 |
| TerSera Therapeutics LLC | $4,864.60 | 10 |
| Gilead Sciences, Inc. | $4,478.86 | 8 |
| Boehringer Ingelheim International GmbH | $4,440.00 | 1 |
| Corcept Therapeutics | $4,048.93 | 3 |
| Roche Products Limited | $2,850.00 | 4 |
| Novartis Pharma AG | $2,800.00 | 1 |
| AstraZeneca UK Limited | $2,327.50 | 4 |
| F. Hoffmann-La Roche AG | $1,845.00 | 1 |
| Davol Inc. | $1,755.00 | 2 |
| PUMA BIOTECHNOLOGY, INC. | $1,600.00 | 1 |
| JAZZ PHARMACEUTICALS INC. | $1,442.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,150.00 | 1 |
| Novartis Pharmaceuticals Corporation | $1,088.97 | 14 |
| Samsung Bioepis Co., Ltd. | $1,061.00 | 2 |
| Tempus AI, Inc | $14.81 | 1 |
Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOYCE ANN O'SHAUGHNESSY
NPI 1790727709 · CMS profile ID 307682
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOYCE ANN O'SHAUGHNESSY, NPI 1790727709, CMS profile ID 307682. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JOYCE ANN O'SHAUGHNESSY, NPI 1790727709, CMS profile ID 307682. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JOYCE ANN O'SHAUGHNESSY, NPI 1790727709, CMS profile ID 307682, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
131 matching records · $132,489.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–131 of 131.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $155.53 | 05/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238005932 | CMS |
| Lilly USA, LLC | $2,625.00 | 04/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186682711 | CMS |
| Eli Lilly and Company | $347.00 | 04/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186662501 | CMS |
| Eli Lilly and Company | $347.00 | 04/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186671509 | CMS |
| Eli Lilly and Company | $16.00 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186671513 | CMS |
| Eli Lilly and Company | $9.00 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186682695 | CMS |
| Eli Lilly and Company | $59.00 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186682697 | CMS |
| Eli Lilly and Company | $151.48 | 04/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186732317 | CMS |
| Eli Lilly and Company | $278.00 | 04/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186732319 | CMS |
| Eli Lilly and Company | $54.00 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186732321 | CMS |
| Eli Lilly and Company | $257.00 | 04/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186744245 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 04/24/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200598301 | CMS |
| PFIZER INC. | $3,748.00 | 04/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231516456 | CMS |
| PFIZER INC. | $750.00 | 04/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231540527 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,000.00 | 04/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206415669 | CMS |
| Merck Sharp & Dohme LLC | $640.00 | 04/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238038532 | CMS |
| AstraZeneca Pharmaceuticals LP | $112.63 | 03/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206793631 | CMS |
| Lilly USA, LLC | $3,937.50 | 03/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186710505 | CMS |
| Eli Lilly and Company | $1,312.50 | 03/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186662499 | CMS |
| PFIZER INC. | $73.88 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231580930 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 03/26/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200598297 | CMS |
| Davol Inc. | $585.00 | 03/19/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232209200 | CMS |
| JAZZ PHARMACEUTICALS INC. | $824.00 | 03/05/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234300687 | CMS |
| Genentech USA, Inc. | $14.93 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211528274 | CMS |
| Stemline Therapeutics Inc. | $38.81 | 02/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244096075 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 02/21/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200598295 | CMS |
| Merck Sharp & Dohme LLC | $2,240.00 | 02/12/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238038214 | CMS |
| Novartis Pharma AG | $2,800.00 | 02/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247622809 | CMS |
| Roche Products Limited | $660.00 | 01/29/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211528286 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 01/23/2025 | Long term medical supply or device loan | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200598293 | CMS |
| Roche Products Limited | $990.00 | 01/22/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211528284 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,692.10 | 1 |
| PY2025 | Principal investigator | $2,197,057.85 | 290 |
| PY2024 | Recipient | $16,309.73 | 6 |
| PY2024 | Principal investigator | $2,131,024.81 | 441 |
| PY2023 | Recipient | $12,701.28 | 3 |
| PY2023 | Principal investigator | $1,471,216.58 | 184 |
| PY2022 | Recipient | $6,226.33 | 7 |
| PY2022 | Principal investigator | $2,253,653.42 | 192 |
| PY2021 | Recipient | $18,330.18 | 12 |
| PY2021 | Principal investigator | $4,264,639.31 | 288 |
| PY2020 | Recipient | $16,390.95 | 17 |
| PY2020 | Principal investigator | $4,218,641.50 | 1,696 |
| PY2019 | Recipient | $8,324.67 | 3 |
| PY2019 | Principal investigator | $2,912,468.34 | 905 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
291 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $753.77 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744792 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $341.35 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744794 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,024.92 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744796 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,270.62 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744798 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,431.55 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744800 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,270.62 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744802 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $390.65 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744804 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744806 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $67,900.40 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology - DFW | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received | No dispute reported | 06/30/2026 | 1232924428 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,553.56 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC | No dispute reported | 06/30/2026 | 1232926043 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,023.80 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology- Plano East | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC | No dispute reported | 06/30/2026 | 1232926267 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,954.96 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology-Baylor Charles A. Sammons Cancer Center | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232926493 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,954.96 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology- Plano East | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232926495 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,402.83 | 12/31/2025 | Non-covered Recipient Entity Texas Oncology-Dallas Presbyterian Hospital | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232927169 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681868 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681878 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 12/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681880 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681882 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 12/19/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677541 |
| Principal investigator 1 | Genentech, Inc. | $23,805.00 | 12/19/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681860 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742964 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 12/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742966 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,246.73 | 12/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742968 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 12/04/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681864 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/04/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681870 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/04/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681884 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/04/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681888 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 12/04/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681892 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 12/03/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211676211 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,205.16 | 11/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744780 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,936.12 | 11/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744782 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,053.00 | 11/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744784 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $137.15 | 11/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744786 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $390.65 | 11/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744788 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 11/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744790 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 11/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681858 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,100.00 | 11/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742493 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 11/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742495 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,486.45 | 11/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742497 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $900.00 | 11/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742962 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 11/14/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681848 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,111.76 | 11/11/2025 | Non-covered Recipient Entity BAYLOR HEALTH CARE SYSTEM / SAMMONS CANCER CENTER | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190313309 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,995.65 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742958 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742960 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10,400.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742489 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $17,000.00 | 11/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742491 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10.00 | 10/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744774 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $975.00 | 10/31/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744776 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 10/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744778 |
| Principal investigator 1 | Exelixis Inc. | $195.00 | 10/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379720 |
| Principal investigator 1 | Exelixis Inc. | $3,380.00 | 10/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379722 |
| Principal investigator 1 | Exelixis Inc. | $300.00 | 10/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379724 |
| Principal investigator 1 | Exelixis Inc. | $1,267.50 | 10/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379726 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,551.50 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742952 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742954 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677507 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 10/22/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677521 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 10/22/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677525 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 10/15/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228723082 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 10/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228726518 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681826 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681832 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681836 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681840 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681842 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $12,723.48 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742487 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742946 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,470.50 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742948 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $16,324.20 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742950 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10,984.28 | 10/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742956 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744682 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,495.00 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744684 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,000.00 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744686 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,495.00 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744688 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,495.00 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744690 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $57.04 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744692 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $197.44 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744694 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,184.63 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744696 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $100.91 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744698 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744700 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744702 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744704 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $118.46 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744706 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,275.01 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744708 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $644.08 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744710 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,290.80 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744712 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $469.03 | 09/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744714 |
| Principal investigator 1 | PFIZER INC. | $3,185.50 | 09/24/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228760234 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681720 |
| Principal investigator 1 | Genentech, Inc. | $1,417.73 | 09/18/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681752 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681768 |
| Principal investigator 1 | Genentech, Inc. | $1,417.73 | 09/18/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681822 |
| Principal investigator 1 | Exelixis Inc. | $50.00 | 09/17/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379700 |
| Principal investigator 1 | Exelixis Inc. | $12,869.03 | 09/17/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379706 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 09/17/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677467 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 08/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744716 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,227.10 | 08/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744718 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $644.08 | 08/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744720 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,492.63 | 08/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744722 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,605.83 | 08/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744724 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $117,954.40 | 08/31/2025 | Non-covered Recipient Entity US Oncology Research, Inc. | STUDY NAME#Pilot clinical trial of treatment with bortezomib to inhibit homologous recombination HR followed by pembrolizumab and cisplatin in patients with chemotherapy-pretreated metastatic triple negative breast cancer | No dispute reported | 06/30/2026 | 1232935517 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681710 |
| Principal investigator 1 | Genentech, Inc. | $265.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681714 |
| Principal investigator 1 | Genentech, Inc. | $45.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681738 |
| Principal investigator 1 | Genentech, Inc. | $1,417.73 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681740 |
| Principal investigator 1 | Genentech, Inc. | $9,522.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681744 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681754 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681774 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681780 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681782 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681792 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681796 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681798 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681808 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681810 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681812 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681814 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 08/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681816 |
| Principal investigator 1 | Genentech, Inc. | $2,098.00 | 08/25/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677477 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 08/21/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681718 |
| Principal investigator 1 | Genentech, Inc. | $20.00 | 08/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677487 |
| Principal investigator 1 | Genentech, Inc. | $12,670.00 | 08/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677495 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 08/07/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681746 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742481 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742483 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,900.00 | 08/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742485 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744726 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,184.63 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744728 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $32.47 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744730 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $74.59 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744732 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $57.04 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744734 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,472.45 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744736 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744738 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744740 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744742 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $302.74 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744744 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $197.44 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744746 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,605.83 | 07/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744748 |
| Principal investigator 1 | Exelixis Inc. | $3,500.00 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379698 |
| Principal investigator 1 | Exelixis Inc. | $7,500.00 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379702 |
| Principal investigator 1 | Exelixis Inc. | $3,629.68 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379704 |
| Principal investigator 1 | Exelixis Inc. | $1,750.00 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379708 |
| Principal investigator 1 | Exelixis Inc. | $1,072.50 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379710 |
| Principal investigator 1 | Exelixis Inc. | $24,030.50 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379712 |
| Principal investigator 1 | Exelixis Inc. | $480.00 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379714 |
| Principal investigator 1 | Exelixis Inc. | $50.00 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379716 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 07/29/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379718 |
| Principal investigator 1 | PFIZER INC. | $7,778.90 | 07/25/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228773821 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 07/23/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677391 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $45,974.51 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185544813 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $95,712.32 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185544809 |
| Principal investigator 1 | PFIZER INC. | $720.00 | 07/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228746036 |
| Principal investigator 1 | PFIZER INC. | $720.00 | 07/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228746226 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 07/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228747974 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,250.00 | 07/09/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) | No dispute reported | 06/30/2026 | 1185544821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,516.00 | 07/09/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287679 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 06/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744750 |
| Principal investigator 1 | PFIZER INC. | $2,021.76 | 06/26/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228776135 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 06/25/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681558 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,457.40 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185544819 |
| Principal investigator 1 | Genentech, Inc. | $3,174.00 | 06/11/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681484 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,470.50 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742477 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10,168.20 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742479 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 05/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744752 |
| Principal investigator 1 | Genentech, Inc. | $10,193.00 | 05/28/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677118 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681486 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681502 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681540 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681610 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681636 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681662 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 05/26/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681666 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 05/19/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681596 |
| Principal investigator 1 | PFIZER INC. | $311.50 | 05/15/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228773419 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,692.10 | 05/13/2025 | Covered Recipient Physician | China IITvsUS Flatiron AB | No dispute reported | 06/30/2026 | 1190292471 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $41,300.00 | 05/09/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas | No dispute reported | 06/30/2026 | 1235993865 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 05/08/2025 | Non-covered Recipient Entity Baylor Sammons Cancer Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228760157 |
| Principal investigator 1 | PFIZER INC. | $2,333.26 | 05/06/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228783560 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 05/05/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677321 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 05/05/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677329 |
| Principal investigator 1 | Genentech, Inc. | $6,348.00 | 05/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681510 |
| Principal investigator 1 | Genentech, Inc. | $290.00 | 05/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681594 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $98,249.96 | 04/30/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185544805 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,834.24 | 04/30/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185544807 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744754 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,472.45 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744756 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $74.59 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744758 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744760 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744762 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,687.43 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744764 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,605.83 | 04/30/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744766 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 04/25/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211676165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,258.00 | 04/16/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,611.00 | 04/16/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287740 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,882.35 | 04/16/2025 | Non-covered Recipient Entity BAYLOR HEALTH CARE SYSTEM / SAMMONS CANCER CENTER | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190313311 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 04/15/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681564 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 04/15/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681580 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 04/15/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681584 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 04/15/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681620 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 04/15/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681626 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 04/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228746040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $176.00 | 04/11/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $94.00 | 04/11/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287714 |
| Principal investigator 1 | Janssen Research & Development, LLC | $94.00 | 04/11/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287775 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379684 |
| Principal investigator 1 | Exelixis Inc. | $2,600.00 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379686 |
| Principal investigator 1 | Exelixis Inc. | $2,600.00 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379688 |
| Principal investigator 1 | Exelixis Inc. | $2,600.00 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379690 |
| Principal investigator 1 | Exelixis Inc. | $2,600.00 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379692 |
| Principal investigator 1 | Exelixis Inc. | $4,225.00 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379694 |
| Principal investigator 1 | Exelixis Inc. | $474.50 | 04/10/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379696 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,100.00 | 04/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742467 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,470.50 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742465 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,100.00 | 04/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742469 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 03/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744768 |
| Principal investigator 1 | Genentech, Inc. | $45.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681448 |
| Principal investigator 1 | Genentech, Inc. | $12,696.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681450 |
| Principal investigator 1 | Genentech, Inc. | $11,728.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681464 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681466 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681478 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681678 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681694 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 03/24/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681700 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 03/24/2025 | Non-covered Recipient Entity Baylor Sammons Cancer Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228770304 |
| Principal investigator 1 | PFIZER INC. | $2,021.76 | 03/22/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228779868 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 03/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677197 |
| Principal investigator 1 | Genentech, Inc. | $20.00 | 03/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677276 |
| Principal investigator 1 | Genentech, Inc. | $247.00 | 03/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677309 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,705.50 | 03/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185544799 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $226,335.00 | 03/06/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY | Patient Journey, Treatment Patterns, and Clinical Outcomes of Women Diagnosed With HR+/HER2 Early-Stage Breast Cancer | No dispute reported | 06/30/2026 | 1190301837 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,500.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742471 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $18,500.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742473 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10,500.00 | 03/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233742475 |
| Principal investigator 1 | PFIZER INC. | $4,626.70 | 03/04/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228783578 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 02/28/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744770 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,587.00 | 02/26/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287579 |
| Principal investigator 1 | Genentech, Inc. | $1,875.00 | 02/19/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677146 |
| Principal investigator 1 | PFIZER INC. | $3,245.02 | 02/19/2025 | Non-covered Recipient Entity Baylor Sammons Cancer Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228770502 |
| Principal investigator 1 | PFIZER INC. | $295.00 | 02/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228750417 |
| Principal investigator 1 | Exelixis Inc. | $2,632.50 | 02/14/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379680 |
| Principal investigator 1 | PFIZER INC. | $4,043.52 | 02/14/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228752871 |
| Principal investigator 1 | PFIZER INC. | $2,271.36 | 02/13/2025 | Non-covered Recipient Entity Texas Oncology PA | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228749395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,411.00 | 02/12/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,587.00 | 02/12/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,411.00 | 02/12/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,125.00 | 02/12/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287697 |
| Principal investigator 1 | Exelixis Inc. | $4,511.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379664 |
| Principal investigator 1 | Exelixis Inc. | $1,852.50 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379666 |
| Principal investigator 1 | Exelixis Inc. | $1,200.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379668 |
| Principal investigator 1 | Exelixis Inc. | $3,510.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379670 |
| Principal investigator 1 | Exelixis Inc. | $2,600.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379672 |
| Principal investigator 1 | Exelixis Inc. | $832.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379674 |
| Principal investigator 1 | Exelixis Inc. | $4,511.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379676 |
| Principal investigator 1 | Exelixis Inc. | $1,072.50 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379678 |
| Principal investigator 1 | Exelixis Inc. | $125.00 | 02/06/2025 | Non-covered Recipient Entity Baylor Scott & White Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379682 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 02/05/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211676152 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681494 |
| Principal investigator 1 | Genentech, Inc. | $64.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681506 |
| Principal investigator 1 | Genentech, Inc. | $293.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681518 |
| Principal investigator 1 | Genentech, Inc. | $106.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681528 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681532 |
| Principal investigator 1 | Genentech, Inc. | $1,350.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681560 |
| Principal investigator 1 | Genentech, Inc. | $114.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681562 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681616 |
| Principal investigator 1 | Genentech, Inc. | $1,363.00 | 02/05/2025 | Non-covered Recipient Entity US Oncology Research, LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211681664 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 02/03/2025 | Non-covered Recipient Entity Baylor Sammons Cancer Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228768885 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 01/31/2025 | Non-covered Recipient Entity Texas Oncology | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233744772 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,176.00 | 01/31/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287611 |
| Principal investigator 1 | PFIZER INC. | $694.00 | 01/27/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228800936 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,844.81 | 01/24/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185544815 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $48,320.94 | 01/22/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INSTITUTE BAYLOR SCOTT AND WHITE RESEARCH INSTITUTE | Assessment of translation biomarkers in patients with chemotherapy-pretreated metastatic triple negative breast cancer who have been treated with bortezomib to inhibit homologous recombination HR followed by pembrolizumab and cisplatin | No dispute reported | 06/30/2026 | 1232937854 |
| Principal investigator 1 | Eli Lilly and Company | $52,623.00 | 01/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187892834 |
| Principal investigator 1 | Genentech, Inc. | $10,672.00 | 01/21/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211677167 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,685.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185544795 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $58,819.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185544797 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $328,063.00 | 01/15/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185544801 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $858.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer | No dispute reported | 06/30/2026 | 1185544803 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $797.78 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) | No dispute reported | 06/30/2026 | 1185544811 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,385.10 | 01/15/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) | No dispute reported | 06/30/2026 | 1185544823 |
| Principal investigator 1 | Eli Lilly and Company | $17,865.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187890542 |
| Principal investigator 1 | Eli Lilly and Company | $37,865.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1187890870 |
| Principal investigator 1 | Eli Lilly and Company | $0.33 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1187893334 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228745774 |
| Principal investigator 1 | PFIZER INC. | $956.00 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS | No dispute reported | 06/30/2026 | 1228746032 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,411.00 | 01/14/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287562 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,176.00 | 01/14/2025 | Non-covered Recipient Entity The Us Oncology Ntwrk | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175287618 |
| Principal investigator 1 | Eli Lilly and Company | $21,290.70 | 01/09/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION | No dispute reported | 06/30/2026 | 1187890538 |
| Principal investigator 1 | Eli Lilly and Company | $25,227.00 | 01/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1187890594 |
| Principal investigator 1 | Eli Lilly and Company | $0.04 | 01/06/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187891756 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $77,337.68 | 01/03/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer | No dispute reported | 06/30/2026 | 1185544817 |
| Principal investigator 1 | Eli Lilly and Company | $83,190.30 | 01/03/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | Not supplied | No dispute reported | 06/30/2026 | 1187892798 |